A Collaborative Approach Sets Worldwide Clinical Trials Apart in Sarcoidosis Research

Sarcoidosis is an inflammatory disease characterized by granulomas forming and potentially interfering with normal organ function, mainly in the lungs and lymph glands. The exact cause is unknown, and there is no cure. However, the disease has a relatively good prognosis with a low rate of mortality, and many patients suffer few symptoms associated with the condition, which are treated with lifestyle modifications and corticosteroids to reduce inflammation when needed. The highly variable nature of the disease creates challenges for researchers seeking to establish clear study protocols and end points.   

As a leader in IMID research, the Worldwide team recognizes the importance of understanding the underlying inflammatory condition behind the presenting symptoms. Such conditions often involve several body systems, so we take a multidisciplinary approach to your clinical trial. And you’ll see that same collaborative approach flow into our relationships with investigator sites, thought leaders in the field, and, of course, our sponsor partners. Our experience in trial design and execution, informed by strong ties to regulatory authorities, empowers us to be a full-service provider for Phase I-IV clinical trials and real-world evidence studies.